Neal Navani, MA, MBBS, MRCP, MSc, PhD, University College London, London, UK, discusses the differences in the application of endobronchial ultrasound (EBUS) and CT-guided biopsies at diagnosis versus repeat biopsy after disease progression (second-line).
Both techniques are well established for diagnosing lung cancer and have traditionally been used for initial diagnosis. However, there is an increasing need to perform a repeat biopsy of tumours that are progressing after first-line treatment. This can provide insights into why the tumour has become resistant to the treatment and inform tailored second-line treatment decisions.
Dr Navani explains differences in the application of these techniques between the first-line and second-line settings, highlighting that patient consent to a repeat biopsy is critical. He also discusses reasons behind the reduced sensitivity of the techniques in the second-line setting and how these need to be reflected when discussing options with patients.
Recorded at the 2017 meeting of the British Thoracic Oncology Group (BTOG) in Dublin, Ireland.